bicalutamide has been researched along with Lower Urinary Tract Symptom in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosnyak, Z; Malmberg, A; Mason, M; Neijber, A; Richaud, P | 1 |
| Ferlicot, S | 1 |
| Cui, Y; Li, N; Yan, H; Zhang, Y; Zong, H | 1 |
| Arai, Y; Hirai, M; Kobayashi, Y; Miyagawa, T; Saito, K; Washino, S | 1 |
| Aaltomaa, S; Axcrona, K; Colli, E; da Silva, CM; Damber, JE; Klarskov, P; Ozen, H; Tankó, LB | 1 |
| Al-Ali, G; Anderson, J; Colli, E; Gomez Veiga, F; Gual, JB; Persson, BE; van der Meulen, E; Wirth, M | 1 |
2 review(s) available for bicalutamide and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
[Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
Topics: Adenocarcinoma; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fatal Outcome; Humans; Leuprolide; Lower Urinary Tract Symptoms; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Odds Ratio; Oligopeptides; Prostatic Neoplasms; Quality of Life; Time Factors; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2014 |
3 trial(s) available for bicalutamide and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome | 2017 |
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2012 |
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Anilides; Drug Therapy, Combination; Early Termination of Clinical Trials; Europe; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nitriles; Oligopeptides; Patient Selection; Prostatic Neoplasms; Sample Size; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
1 other study(ies) available for bicalutamide and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Nocturia; Organ Size; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Tosyl Compounds | 2018 |